English
Swedish
Home
About DexTech
Analysis
Technology
Clinical Research
Prostate cancer
Investors
Press releases
Contact
Home
About DexTech
Analysis
Technology
Clinical Research
Prostate cancer
Investors
Press releases
Contact
251016 – PR – DexTech – Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3
16 October, 2025
251016 - PR - DexTech - Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3
«
DexTech Medical’s Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3
We use cookies to ensure that we give you the best experience on our website.
If you continue to use this site we will assume that you are happy with it.
Ok